Medarex Announces Webcast of MDX-010 Clinical Results Following ASCO Presentations
PRINCETON, N.J., May 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) will hold a live webcast of data from the MDX-010 clinical trial studies in prostate cancer and malignant melanoma being presented at the 38th Annual Meeting of the American Society of Clinical Oncology.
Dr. James Allison, Howard Hughes Investigator and Professor of Immunology and Director of the Cancer Research Laboratory at the University of California, Berkeley, will join Dr. Thomas Davis, Senior Director of Clinical Science, and Dr. Nils Lonberg, Senior Vice President and Scientific Director, both from Medarex, to provide an overview of MDX-010, including a review of certain clinical trial results presented earlier at the conference.
The webcast will begin Wednesday, May 22, 2002 at 4:30 PM Eastern time and may be accessed through the Medarex website at medarex.com. Investors interested in listening to the webcast should log on before the presentation begins in order to download any software required. An archive of the presentation will be available on the Medarex website for at least 14 days.
and from an October 31, 2001 Press Release.
Initial Results of First Human Clinical Trial Using MDX-010 Announced
PRINCETON, N.J., Oct. 30 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX) today reported interim findings of ongoing Phase I/II clinical trials of a fully human antibody product, MDX-010, in patients with advanced melanoma or
prostate cancer. The findings were presented at the Strategic Research Institute Anti-Cancer Drug Discovery and Development Summit held last week in San Francisco, CA.
In the initial human clinical trials, 18 patients with metastatic melanoma and 14 patients with hormone refractory prostate cancer received a single 3 mg/kg dose of the antibody. The data indicate that the product was
generally well tolerated. Of adverse events reported, more than 97% were mild to moderate (grade 1 and 2). Signs of immunologic activity included tumor necrosis, inflammatory reactions at tumor sites and relief of symptoms. In
addition, after receiving a single dose of MDX-010, two patients with prostate cancer experienced a greater than 50% reduction in serum prostate specific antigen (PSA) measurement that lasted from 3 to 6 months. PSA levels are
generally considered to be a marker of disease progression in prostate cancer patients. Based upon this experience, further clinical trials are being initiated that will test repeated dosing of the antibody used alone, as well
as combinations of the antibody and other anti-cancer therapies.
"Although these initial single dose trials were designed to test primarily for safety, we are excited that the interim results also showed evidence of anti-tumor activity," said Donald L. Drakeman, President and CEO of Medarex.
MDX-010 (formerly MDX-101) is a fully human antibody against human CTLA-4, a molecule on T cells that is responsible for suppressing the immune response. Studies in mice have demonstrated that an antibody against CTLA-4 is able to
strengthen the innate immune response against certain tumors, leading to the reduction of and, in some cases, the elimination of well-established tumors. |
